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During early 2017, we conducted a seroepidemiologic in-
vestigation for tickborne encephalitis virus among 291 Ja-
pan Self-Defense Forces members in Hokkaido. Two (0.7%) 
tested positive. Neither had clinically apparent symptoms 
after removing ticks.
Tickborne encephalitis virus (TBEV; genus Flavivirus, family Flaviviridae) persists in ticks and wild animals, 
including wild rodents and shika deer (1,2). Geographically, 
the virus is widely spread across Eurasia and annually causes 
≈10,000 clinically apparent cases in humans (3). In Japan, 
tickborne encephalitis is notifiable. Two confirmed cases, 
both in Hokkaido in the northernmost prefecture, have been 
reported. The first confirmed case was serologically diag-
nosed in 1993 (4); the second case was confirmed in 2016.
During the 20-year gap between cases, serologic and 
virologic surveys of wild animals (5,6) clarified that TBEV 
has been maintained in animal populations, especially in 
wild rodents in Hokkaido. Given the continued ecologic 
findings of virus activity in animals, it is plausible that hu-
mans have acquired TBEV infection, especially persons 
frequently exposed to ticks, including Japan Self-Defense 
Forces (JSDF) members of the Northern Army. We report 
the result from a pilot seroepidemiologic study of JSDF 
members conducted to determine the presence of unrecog-
nized infections and to crudely measure the frequency.
We recruited 291 JSDF members who belong to the 
Northern Army and who received tick bites during ground 
activities (7). During their general health screening in Feb-
ruary and March 2017, participants were asked to provide 
an additional 2 mL of serum for laboratory testing and to 
answer a questionnaire about the frequency of tick bites. 
We conducted neutralizing antibody testing using the virus 
isolated from Hokkaido in 1993 (4). We determined a se-
rum sample to be TBEV positive if >50% plaque reduction 
compared with healthy human control serum was observed. 
We defined neutralizing titer as the reciprocal of the high-
est dilution of serum. To differentiate TBEV infection from 
Japanese encephalitis virus (JEV) infection, which occurs 
in southwestern Japan, we also conducted neutralization 
testing for JEV on all TBEV positive samples.
The Medical Ethics Committees at the Graduate 
School of Medicine, Hokkaido University and JSDF Sap-
poro Hospital approved this study. The research team ex-
plained to participants that the enrollment was voluntary 
and gave participants the right to withdraw. We obtained 
written informed consent from participants, and no names 
were assigned to serum samples or questionnaires.
Participants ranged in age from 35 to 54 years (mean 
43.3 years). A total of 288 (99.0%) of the 291 participants 
were men. Ninety-two  (31.6%; 95% CI 26.5%–37.1%) 
participants appeared to have been bitten by ticks >1 
time during the previous 10 years; participants were bit-
ten a mean of 1.4 (SD ± 1.1) times. Two (0.7%; 95% CI 
0.0%–1.7%) persons appeared to have been infected with 
TBEV; both were negative for JEV, the only other flavi-
virus in Japan. The TBEV-positive participants were men 
42 and 48 years of age who had been bitten 3 and 1 times, 
respectively, within the previous 10 years (Table). Neither 
man complained of symptoms of TBEV infection, such as 
high-grade fever, headache, nausea, or paralysis after tick 
removal; however, the 48-year-old participant noted right 
knee joint pain, inguinal lymph node swelling, and low-
grade fever, which he attributed to the remaining body part 
of a tick.
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 10, October 2017 1753
RESEARCH LETTERS
These 2 unrecognized subclinical TBEV infections 
were serologically diagnosed, demonstrating that humans 
who are particularly at risk for tick bites are partly asymp-
tomatically infected with TBEV in Hokkaido. Because 
flaviviruses are known to serologically cross-react with 
other close flaviviruses (8), we tested serum against JEV, 
the only other endemic flavivirus in Japan, and successfully 
excluded its possibility. The antibody titer was lower than 
that in persons with clinically apparent cases (e.g., >1,600), 
perhaps because the virus replication was limited among 
subclinical cases or antibody had decayed since infection. 
Our findings echo similar cross-sectional survey results 
among persons recently bitten by ticks in Xinjiang and In-
ner Mongolia, China (9). Although the estimated frequency 
in Japan was as low as 0.7%, this figure should not be re-
garded as small, considering that >30,000 persons serve in 
the Northern Army. In addition, frequently bitten persons 
include not only JSDF members but also dairy farmers, for-
esters, and hikers. Seroepidemiologic survey with greater 
sample size and broader scope of study participants are 
needed to identify persons at high risk for infection and 
determine the pros and cons of specific countermeasures, 
including vaccination (10). Such surveys also are needed to 
measure the virulence of TBEV of the so-called Far-East-
ern subtype because the detection of subclinical or mild 
cases may lead to an overall decrease in its case-fatality 
risk, which is perceived as high (1).
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Table. Neutralizing antibody titers against TBEV and JEV among 








42 3 times 80 <20 
48 1 time 40 <20 
*JEV, Japanese encephalitis virus; TBEV, tickborne encephalitis virus. 
†Neutralizing titer was defined as the reciprocal of the highest dilution of 
serum. 
 
